BTOG 2024 | Managing lung cancer patients with ILD: the oncology perspective

Matthew Hatton, MBChB, MSc, FRCP, FRCR, University of Sheffield, Sheffield, UK, discusses the challenges of managing lung cancer in patients with interstitial lung disease (ILD), emphasizing ILD as a pre-malignant condition. He notes that such patients often present with non-small cell lung cancer (NSCLC), typically in early stages, yet face complexities due to co-existing respiratory comorbidities. While literature suggests standard lung cancer treatments may be effective, these patients are more prone to toxicities, particularly respiratory ones. Thus, personalized treatment decisions are crucial, considering the balance between treatment benefits and risks. Prof. Hatton underscores the need for individualized research to explore better treatment options for this patient group, including investigating established ILD treatments like fibrinolytic agents for potential protective effects against treatment-related side effects. This interview took place at the BTOG 2024 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.